K. Enya

发表

Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus

K. Kaku, K. Enya, Kenkichi Sugiura, 2011, Current medical research and opinion.

Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study

H. Rakugi, K. Enya, Kenkichi Sugiura, 2012, Hypertension Research.

The interaction with Sp1 and reduction in the activity of histone deacetylase 1 are critical for the constitutive gene expression of IL‐1α in human melanoma cells

H. Hayashi, T. Okamoto, K. Onozaki, 2008, Journal of leukocyte biology.

The interaction with Sp 1 and reduction in the activity of histone deacetylase 1 are critical for the constitutive gene expression of IL-1 in human melanoma cells

H. Hayashi, T. Okamoto, K. Onozaki, 2007 .

Pharmacokinetics of a Single Dose of Azilsartan in Pediatric Patients: A Phase 3, Open-Label, Multicenter Study

H. Okamoto, K. Enya, B. Saji, 2018, Advances in Therapy.

Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.

J. DeJongh, M. Danhof, K. Kaku, 2015, Diabetes technology & therapeutics.

Evaluation of the Long-term Durability and Glycemic Control of FPG and HbA1c for Pioglitazone in Japanese Patients with Type 2 Diabetes

J. DeJongh, M. Danhof, K. Enya, 2015 .

Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women.

Y. Osuga, H. Hoshiai, K. Enya, 2019, Fertility and sterility.

Effect of azilsartan versus candesartan on morning blood pressure surges in Japanese patients with essential hypertension

K. Kario, H. Rakugi, K. Enya, 2014, Blood pressure monitoring.

Safety and efficacy of azilsartan in paediatric patients with hypertension: a phase 3, single-arm, open-label, prospective study

S. Ito, K. Enya, Kenkichi Sugiura, 2021, Clinical and Experimental Nephrology.

Long‐term safety and efficacy of fasiglifam (TAK‐875), a G‐protein‐coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52‐week open‐label phase III study

K. Kaku, K. Enya, T. Ohira, 2016, Diabetes, obesity & metabolism.

Effect of azilsartan versus candesartan on nocturnal blood pressure variation in Japanese patients with essential hypertension

K. Kario, H. Rakugi, K. Enya, 2013, Blood pressure.

Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis.

K. Tohyama, Shuntarou Tsuchiya, K. Enya, 2018, Biochemical and biophysical research communications.

Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.

Y. Osuga, H. Hoshiai, K. Enya, 2019, Obstetrics and gynecology.

Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial

K. Kaku, K. Enya, T. Ohira, 2015, Diabetes, obesity & metabolism.

1209P A phase II study of regorafenib in combination with nivolumab in patients with recurrent or metastatic solid tumors: Results of the ESCC cohort

B. Keam, I. Waxman, S. Pernot, 2022, Annals of Oncology.

Increasing orphan drug loss in Japan: Trends and R&D strategy for rare diseases.

S. Sengoku, Kota Kodama, Yeongjoo Lim, 2023, Drug discovery today.